Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Fast-moving stars in the Milky Way indicate there could be a supermassive black hole in the neighboring Large Magellanic ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Operatives working for Elon Musk’s DOGE appear to be editing the code of AutoRIF—software designed by the Defense Department ...

Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...

The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Health sector stocks fluctuate amid DOJ probe into UnitedHealth (UNH), Gilead upgrade for HIV treatments, and Moderna's focus on non-COVID approvals.

A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...